The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs : A Meta-Analysis
Zuellig, J.A. (University of Basel)
Adam, Roman (University of Basel)
Udry, F. (University of Basel)
Tibau Martorell, Ariadna (Institut de Recerca Sant Pau)
Šeruga, B. (Univerza V Ljubljani)
Ocaña, A. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Amir, Eitan (University of Toronto)
Templeton, A.J. (St. Clara Research)
Universitat Autònoma de Barcelona. Departament de Medicina

Fecha:	2025
Resumen:	Background/Objectives: To study whether shorter restaging intervals are associated with lower hazard ratios (HRs) for progression-free survival (PFS), as suggested in breast cancer. Methods: Studies supporting the registration of oncologic drugs in Switzerland from 2010 to 2022 were analyzed. HRs and 95% confidence intervals (CIs) for PFS were pooled in a meta-analysis using the generic inverse-variance method and a random-effects model in RevMan v5. 4. The HRs were stratified by restaging intervals (<median vs. ≥median), both overall and within prespecified subgroups. Results: A total of 112 studies comprising 69,579 patients were included. The median restaging interval was 8 weeks, with a range of 4 to 18 weeks. Longer restaging intervals (≥8 weeks) were associated with lower HRs compared to shorter intervals (<8 weeks), with pooled HRs of 0. 48 (95% CI: 0. 44-0. 52) and 0. 58 (95% CI: 0. 53-0. 63), respectively. The difference between the groups was statistically significant (p = 0. 005), with a substantial heterogeneity (Cochran's Q p < 0. 001; I = 90%). Subgroup analyses based on treatment type, including immunotherapy, monoclonal antibodies, and tyrosine kinase inhibitors, did not show any statistically significant differences in HRs. Studies of melanoma with shorter staging intervals were associated with lower HRs (0. 44 vs. 0. 58, p = 0. 02), whereas shorter interval studies of kidney cancer had higher HRs (0. 67 vs. 0. 44, p = 0. 01). Sensitivity analyses with other cut-offs and a meta-regression yielded similar results. Conclusions: Studies leading to the authorization of drugs to treat incurable solid tumors applying restaging intervals ≥ 8 weeks were associated with lower HRs for PFS. The potential impact of restaging intervals on the results for PFS warrants further investigation.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Meta-analysis ; Oncologic drug ; Registration trial ; Staging
Publicado en:	Cancers, Vol. 17 Núm. 8 (april 2025) , p. 1359, ISSN 2072-6694

DOI: 10.3390/cancers17081359
PMID: 40282533

11 p, 1.3 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados